Selank
Also known as: Tuftsin analog, Thr-Lys-Pro-Arg-Pro-Gly-Pro
Selank (also called Tuftsin analog or Thr-Lys-Pro-Arg-Pro-Gly-Pro) is an anxiolytic tuftsin analog in the Neuromodulator class. Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation.
For research use only.
Key Facts
- CAS
- 129954-34-3
- Molecular Weight (MW)
- ≈751.9 g/mol
- Half-life
- Not established (varies by route; nasal studied in RU)
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GABAergic systemsEnkephalin metabolism
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Dec 2025 and Sep 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 34
- Listed offers
- 56
- Median price per mg
- $4.50/mg
- Typical $3.65–$6.81/mg
Research summary
Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language.
Peptide Library's Selank profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Selank dosage: no established human dose
Selank has no established human dosage outside Russia. The human clinical literature consists of a small number of Russian-language studies in anxiety disorders, published in a single national journal, whose full protocols and doses are not available in the English-language indexed record. Selank is not approved in the United States or the European Union, and no trial is registered on ClinicalTrials.gov.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Selank is a synthetic analogue of the endogenous peptide tuftsin, developed in Russia, with preclinical work on anxiolytic and neuroprotective effects in rodents. The human evidence that exists is clinical rather than preclinical, but it is concentrated in one national journal, is not replicated in trials registered internationally, and does not report doses in the indexed English-language record. No dose is established that this profile can cite.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Intranasal (the route used in the Russian clinical literature) |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-05 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Russian clinical study — anxiety disorders (2015)Clinical trial · Clinical study, Russian-language publication | Patients with anxiety disorders | Not available in the indexed English record | Intranasal | — | — | Anxiety symptom severity | Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. |
| Comparison with phenazepam (2014)Clinical trial · Comparative clinical study, Russian-language publication | Patients with anxiety disorders | Not available in the indexed English record | Intranasal | — | — | Anxiolytic effect and tolerability versus phenazepam | A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of generalized anxiety disorder. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. |
| Early clinical report (2008)Clinical trial · Clinical study, Russian-language publication | Patients with anxiety disorders | Not available in the indexed English record | Intranasal | — | — | Efficacy and mechanisms | Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. |
Where sources disagree
- Protocols of roughly 250–500 mcg intranasally per day are commonly published for selank. The Russian clinical literature is the likely origin of figures in this range, but the doses are not retrievable from the indexed record, so this profile does not restate them as established.
- No selank trial is registered on ClinicalTrials.gov and no regulator in the United States or European Union has approved it. Its use as a registered medicine in Russia does not transfer an approved dose to other jurisdictions.
Reconstitution
Common research vial sizes: 5 mg, 10 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg per 0.01 mL |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Sequence & molecular data
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
|---|---|
| Molecular formula | C33H57N11O9 |
| Molecular weight | ≈751.9 g/mol |
| CAS number | 129954-34-3 |
| Half-life | Not established (varies by route; nasal studied in RU) |
| Appearance | White lyophilized powder or solution (often nasal in RU) |
| Formulation | Lyophilized Powder |
| PubChem CID | 11765600 |
| FDA UNII | TS9JR8EP1G |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. Reported activity in animal and small human studies centres on anxiolysis without sedation or dependence: it has been described as modulating GABA-A receptor expression and monoamine turnover, and as inhibiting enkephalin-degrading enzymes, which raises endogenous enkephalin tone. Its tuftsin ancestry also gives it reported immune-modulating activity, including effects on interleukin-6. Most of the literature is Russian-language, where it is used clinically for anxiety disorders; it has no FDA-approved use and independent replication is limited.
Origin
Synthetic Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Targets
Studies
- [Optimization of the treatment of anxiety disorders with selank]
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress
Regulatory & research status
Selank is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
Benefits
Selank side effects
Selank has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Nasal irritation (intranasal)
- Fatigue
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Selank: frequently asked questions
What is Selank?
Synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a stabilising tail, developed in Russia as an anxiolytic and most often used intranasally. It has been studied for anxiety without the sedation or dependence associated with benzodiazepines, and retains some immune-modulating activity from its tuftsin origin. Not FDA-approved; the supporting clinical literature is largely Russian-language. Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation.
What are the side effects of Selank?
Selank has only limited human data, so its side-effect profile is not well established. Effects recorded on this profile include nasal irritation (intranasal) and fatigue. This is reference information, not medical advice.
How does Selank work?
Selank is a synthetic heptapeptide combining the immunomodulatory tetrapeptide tuftsin with a Pro-Gly-Pro tail that slows enzymatic degradation. Reported activity in animal and small human studies centres on anxiolysis without sedation or dependence: it has been described as modulating GABA-A receptor expression and monoamine turnover, and as inhibiting enkephalin-degrading enzymes, which raises endogenous enkephalin tone.
Is Selank FDA approved?
No. Selank is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Selank?
Reported half-life for Selank is Not established (varies by route; nasal studied in RU). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Selank?
Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, giving a chain of 7 amino acids. Its molecular formula is C33H57N11O9.
What peptides are similar to Selank?
Compounds most often compared with Selank include Semax, N-Acetyl Semax Amidate, Adamax and Cerebrolysin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
Where is Selank administered in research protocols?
Research protocols on this profile use intranasal or parenteral in research settings administration. Route affects absorption and stability, so published pharmacokinetic data for one route do not transfer to another.
References
- [Optimization of the treatment of anxiety disorders with selank] — Zh Nevrol Psikhiatr Im S S Korsakova, 2015External reference
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia] — Zh Nevrol Psikhiatr Im S S Korsakova, 2008External reference
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders] — Zh Nevrol Psikhiatr Im S S Korsakova, 2014External reference
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats — Bull Exp Biol Med, 2022External reference
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress — Curr Rev Clin Exp Pharmacol, 2021External reference
Related research, comparisons & guides
- Semax vs. Selank: Two Russian Peptides That Are Not Interchangeable
- Selank Dosage: What the Nasal Route Changes
- Semax Benefits: What the Research Reports and How to Weigh It
- Dihexa: The Angiotensin IV Analogue and Its Very Preclinical Evidence
- Semax
- Cognitive and nootropic peptidesCategory
- Peptide stacks: combinations by research goalStacks
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the Selank preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 5
This Selank profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Selank research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →